Novel drug candidate, MRX-I, an oral oxazolidinone showed positive top-line results from the first Phase 2 clinical study in China, according to biopharmaceutical company, MicuRx Pharmaceuticals,...
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.